Nanoencapsulation increases (−)‐epigallocatechin gallate stability and its cellular bioavailability in macrophages

• DOI: 10.1096/fasebj.26.1_supplement.646.5
• Publication Date: 2021-06-21T15:51:30Z
• Authors: Shu Wang; Jia Zhang; Ming Sun; Zhaoyang Fan
• Keywords: Nanocarriers; Gallate

Atherosclerotic cardiovascular disease is the leading cause of death in U.S. Macrophages are major cells responsible for atherosclerotic lesion development. (−)‐Epigallocatechin gallate (EGCG) abundant green tea valuable prevention and treatment atherosclerosis. But low levels stability bioavailability limit its application human. We encapsulated EGCG into biocompatible biodegradable nanocarriers to increase cellular bioavailability. The nanoencapsulated native was measured at pH 7.2 4 °C 25 °C. Nanoencapsulated separated from nonencapsulated using a Sephadex™ G‐25 column. Total high‐performance liquid chromatography (HPLC) system. uptake by THP‐1 derived macrophages same HPLC Nanoencapsulation significantly increased compared EGCG. This innovation portends potential breakthrough atherosclerosis natural compounds with minimized immunogenicity side‐effects. Grant Funding Source : NIH 1R15AT007013‐01